- Investing.com
Metrics to compare | BOLT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBOLTPeersSector | |
|---|---|---|---|---|
P/E Ratio | - | −1.8x | −0.2x | |
PEG Ratio | −0.01 | −0.05 | 0.00 | |
Price/Book | - | 2.5x | 2.6x | |
Price / LTM Sales | - | 11.2x | 2.8x | |
Upside (Analyst Target) | - | 116.5% | 65.5% | |
Fair Value Upside | Unlock | 20.9% | 8.9% | Unlock |
Bolt Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company offers product candidates and platform technologies, including PRA-216, BDC-4182, a Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; the Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform, and the INSPIRE platform. It serves patients, clinical investigators, and biopharmaceutical partners. The company is based in Redwood City, California.